Michele Holcomb
Executive Vice President,
Chief Strategy and Business Development Officer
Michele Holcomb serves as the Executive Vice President, Chief Strategy & Business Development at Cardinal Health.
She leverages an enterprise perspective to work with leaders across the Pharmaceutical and Medical segments to define strategies and identify opportunities for growth in the evolving healthcare landscape. Her team also supports the execution and integration of innovation and acquisitions, partnerships and divestitures to support Cardinal Health strategy. Areas of focus range from core strategies to developing new business areas to analyzing disruptive challenges and opportunities.
Holcomb came to Cardinal Health from Teva Pharmaceuticals where she was the Chief Operating Officer of Global R&D and Senior Vice President of Strategy, Portfolio, Search and Partnerships. In this role, she led many aspects of R&D operations, including portfolio management of assets across the internal R&D pipeline and external opportunities. She also developed approaches for creative partnerships and external pipeline funding. Holcomb joined Teva in 2010 as the vice president of Corporate Strategy where she led company-wide strategy, including assessment and integration of major acquisitions. She also drove process improvements at key interfaces in R&D, Sales & Marketing and Supply Chain.
Prior to joining Teva, Holcomb was a partner in the Global Pharmaceutical Practice at McKinsey & Company where she served many of the top 10 global pharmaceutical companies, as well as high-growth biotechs, in areas across strategy, business development, R&D and commercialization.
Holcomb is trained as a chemist, with a bachelor’s degree from Stanford University, a doctorate from the University of California, Berkeley, and experience as a bench chemist at Syntex Pharmaceuticals and Ciba-Geigy.
She sits on the Editorial Advisory Board of Pharmaceutical Executive and the Cardinal Health Foundation Board. She is a member of the board of Kimball Electronics Inc, Vineti Inc., Rev1 Ventures, as well as the Columbus BalletMet and New Jersey’s Liberty Science Center.
